Table 2. Factors affecting glycated hemoglobin as determined by the multiple linear regression analysis.
| Insulin monotherapy | Insulin + OAD | |||||||
|---|---|---|---|---|---|---|---|---|
| GPs | Specialists | GPs | Specialists | |||||
| β (95% CI) | P | β (95% CI) | P | β (95% CI) | P | β (95% CI) | P | |
| Age | −0.11 (−0.22 to −0.005) | 0.002 | −0.17 (−0.04 to −0.001) | 0.04 | −0.23 (−0.04 to 0.02) | 0.000 | −0.04 (−0.04 to 0.03) | 0.73 |
| Male sex | −0.04 (−0.140 to 0.043) | 0.30 | 0.007 (−0.19 to 0.21) | 0.93 | −0.0002 (−0.12 to 0.12) | 1.00 | 0.009 (−0.31 to 0.33) | 0.95 |
| BMI | 0.03 (−0.015 to 0.035) | 0.43 | −0.1 (−0.09 to 0.02) | 0.25 | 0.08 (−0.006 to 0.06) | 0.10 | 0.17 (−0.05 to 0.17) | 0.27 |
| Total insulin dose | 0.13 (0.004 to 0.14) | 0.001 | 0.32 (0.01 to 0.05) | 0.001 | 0.03 (−0.005 to 0.008) | 0.62 | 0.06 (−0.02 to 0.03) | 0.70 |
| Use of human (not analog) insulin | 0.01 (−0.09 to 0.13) | 0.73 | −0.09 (−0.34 to 0.11) | 0.31 | 0.11 (0.02 to 0.31) | 0.02 | −0.1 (−0.45 to 0.20) | 0.45 |
| Type of insulin | ||||||||
| Basal | 0.07 (−0.05 to 0.48) | 0.11 | 0.08 (−0.31 to 0.75) | 0.41 | 0.08 (−0.15 to 0.58) | 0.25 | 0.02 (−0.85 to 0.96) | 0.90 |
| Premixed | 0.11 (0.07 to 0.44) | 0.006 | 0.16 (−0.01 to 0.70) | 0.06 | 0.05 (−0.20 to 0.44) | 0.46 | −0.15 (−1.05 to 0.35) | 0.32 |
| Bolus | −0.004 (−0.28 to 0.26) | 0.93 | −0.01 (−0.66 to 0.57) | 0.89 | 0.06 (−0.19 to 0.66) | 0.28 | −0.02 (−1.12 to 0.94) | 0.86 |
| Basal–bolus | −0.05 (−0.44 to 0.10) | 0.21 | −0.15 (−0.89 to 0.05) | 0.08 | 0.04 (−0.35 to 0.74) | 0.49 | −0.19 (−2.24 to −9.78) | 0.14 |
| Premixed‐bolus | 0.005 (−0.39 to 0.44) | 0.91 | 0.58 (−0.84 to 0.48) | 0.58 | −0.1 (−1.90 to 0.30) | 0.15 | 0.15 (−0.60 to 2.13) | 0.27 |
| No. combined OAD | −0.03 (−0.88 to 0.68) | 0.81 | 0.44 (−0.88 to 2.93) | 0.29 | ||||
| Type of OAD | ||||||||
| Glinide | −0.09 (−1.11 to 0.56) | 0.52 | 0.09 (−0.94 to 1.37) | 0.41 | ||||
| SU | 0.04 (−0.26 to 0.42) | 0.66 | −0.12 (−1.00 to 0.57) | 0.59 | ||||
| BG | −0.09 (−0.63 to 0.19) | 0.29 | 0.33 (−0.18 to 1.33) | 0.13 | ||||
| α‐GI | −0.06 (−0.39 to 0.20) | 0.52 | 0.22 (−0.31 to 1.05) | 0.28 | ||||
| TZD | 0.11 (−0.18 to 0.79) | 0.22 | −0.03 (−1.17 to 1.04) | 0.90 | ||||
α‐GI, α‐glucosidase inhibitor; β, standard regression coefficiency; BG, biguanide; BMI, body mass index; CI, confidence interval; GP, general practitioner; OAD, oral antidiabetic; SU, sulfonylurea; TZD, thiazolidinedione.